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Despite Euphorbia hirta L. ethnomedicinal benefits, very few studies have described the potential toxicity. The aim of the present
study was to evaluate the in vivo toxicity of methanolic extracts of E. hirta. The acute and subchronic oral toxicity of E. hirta was
evaluated in Sprague Dawley rats. The extract at a single dose of 5000mg/kg did not produce treatment related signs of toxicity
or mortality in any of the animals tested during the 14-day observation period. Therefore, the LD 50 of this plant was estimated
to be more than 5000mg/kg. In the repeated dose 90-day oral toxicity study, the administration of 50mg/kg, 250mg/kg, and
1000mg/kg/day of E. hirta extract per body weight revealed no significant difference (𝑃 > 0.05) in food and water consumptions,
bodyweight change, haematological and biochemical parameters, relative organweights, and gross findings compared to the control
group. Macropathology and histopathology examinations of all organs including the liver did not reveal morphological alteration.
Analyses of these results with the information of signs, behaviour, and health monitoring could lead to the conclusion that the
long-term oral administration of E. hirta extract for 90 days does not cause sub-chronic toxicity.
1. Introduction
Medicinal plants, either as an extract, pure compound or as a
derivative, offer unlimited opportunities for the discovery of
new drugs. Most of the natural products used in folk remedy
have solid scientific evidence with regard to their biological
activities. However, there is little information or evidence
available concerning the possible toxicity that medicinal
plants may cause to the consumers [1]. In relation to drug
discovery and development, there are different weights of
concern of all relevant groups such as health authorities,
pharmaceutical industry, and patients which need to be
taken into consideration [2]. The general public, patients
and consumers are primarily interested in fast access to safe
and efficient drugs, as well as in animal welfare. Based on
their long-term use by humans one might expect plants used
in traditional medicine to have low toxicity. Nonetheless,
the latest surveys have indicated that many medicinal plants
applied in traditional medicine showed adverse effects [3,
4]. Therefore, it should be emphasized that the traditional
use of any plant for medicinal purposes, by no means,
guarantees the safety of such plant. This raises concern about
the potential toxic effects resulting from the short-term and
long-term use of such medicinal plants. The data of the
acute and subchronic toxicity studies on medicinal plants
or preparations derived from them should be obtained in
order to increase the confidence in their safety to humans,
particularly for use in the development of pharmaceuticals
[5]. Therefore, evaluating the toxicological effects of any
medicinal plant extract intended to be used in animals or
humans is a crucial part of its assessment for potential toxic
effects.
Euphorbia hirta L., which belongs to the family Euphor-
biaceae, is a small annual herb common to tropical countries.
It is usually erect, slender-stemmed and spreads up to
80 cm tall, although sometimes it can be seen lying down.
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The plant is an annual broad-leaved herb that has a hairy
stem with many branches from the base to the top.The leaves
are opposite, elliptical, oblong or oblong-lanceolate, with a
faintly toothed margin, and darker on the upper surface.
The flowers are small, numerous, and crowded together in
dense cymes (dense clusters in upper axils) about 1 cm in
diameter. The stem and leaves produce a white or milky
juice when cut. The plant is frequently seen occupying open
waste spaces, banks of watercourses, grasslands, roadsides,
and pathways [6, 7]. E. hirta is a very popular herb amongst
practitioners of traditional medicine and is widely used as
a decoction or infusion to treat various ailments includ-
ing intestinal parasites, diarrhoea, peptic ulcers, heartburn,
vomiting, amoebic dysentery, asthma, bronchitis, hay fever,
laryngeal spasms, emphysema, coughs, colds, kidney stones,
menstrual problems, sterility, and venereal diseases. More-
over, the plant is also used to treat affections of the skin and
mucous membranes, including warts, scabies, tinea, thrush,
aphthae, fungal afflictions, measles, and guinea-worm and as
an antiseptic to treat wounds, sores, and conjunctivitis. The
plant has a reputation as an analgesic to treat severe headache,
toothache, rheumatism, colic, and pains during pregnancy. It
is used as an antidote and pain relief of scorpion stings and
snakebites. The use of the latex to facilitate the removal of
thorns from the skin is common [8].The sedative, anxiolytic,
analgesic, antipyretic, and anti-inflammatory properties of E.
hirta have been reported in the literature [9]. The leaf extract
of E. hirta increased urine output and electrolytes in rats
[10]. Furthermore, studies revealed that E. hirta possesses
galactogenic, antianaphylactic, antimicrobial, antioxidant,
anticancer, antifeedant, antiplatelet aggregation and anti-
inflammatory, aflatoxin inhibition, antifertility, anthelmintic,
antiplasmodial, antiamoebic, antimalarial, larvicidal, and
repellent and antifeedant activities against Plutella xylostella
[6].
Recent studies also reported the standardization of E.
hirta methanol extract with respect to authenticity, assay,
and chemical constituent analysis by Kwan et al. [11]. The
results of the pharmacognostical standardization of this plant
from their studies serve as a reference and help in future
the identification and authentication of this plant specimen.
Kwan et al. [12] also tested the genotoxicity of E. hirta by
using Allium cepa assay. The results of this study confirmed
that the methanol extracts of E. hirta exerted significant
genotoxic and mitodepressive effects at 1,000 𝜇g/mL. Rajeh
et al. [13] also reported preliminary oral acute toxicity of
E. hirta leaf methanol extract. They reported that E. hirta
leaves methanol extract exhibited mild toxic effects in mice
at a dose of 5000mg/kg body weight. Moreover, Rajeh et al.
[13] also reported the cytotoxicity activity of E. hirta leaves,
stems, flowers, and roots methanol extracts by using brine
shrimp lethality assay. LC
50
values of 1.589, 1.420, 0.206, and
0.0827mg/mL were obtained from stems, leaves, flowers,
and roots of E. hirta, respectively. They observed that the E.
hirta leaves and stems might be nontoxic, and, in contrast,
the flowers and roots might be toxic to the brine shrimp
(A. salina) used in their study. Based on E. hirta use in
traditional practices and the literature references, the present
study was undertaken to evaluate the comprehensive acute
and subchronic toxicity in the animal model and is reported
hereunder.
2. Materials and Methods
2.1. Preparation of Euphorbia hirta Methanol Extract. Sam-
ples of E. hirtawere collected from various areas in Universiti
Sains Malaysia, Penang, in January 2012 and were identified
by Mr. Shanmugam Vellosamy at the Herbarium School of
Biological Sciences, Universiti Sains Malaysia, Pulau Pinang,
Malaysia, where the voucher specimen was deposited (num-
ber USM/HERBARIUM/11215). All the samples of E. hirta
were thoroughly rinsed with tap water and distilled water
before being air-dried at room temperature for 7 days. Then,
the plant sample was ground to a fine powder and soaked
in absolute methanol for 4 days with frequent agitation at
room temperature. The extract was filtered with Whatman
paper no. 1 and the residue of fine powder was then re-
soaked with a fresh portion of methanol twice for four
days each time at room temperature. The filtrate was then
concentrated by rotary evaporator under reduced pressure.
The yield of the extract was 17.1% based on dry weight. The
dried residue of plant extract was resuspended in DMSO
(Sigma, USA) for further biological assay. To standardize
the fingerprint of E. hirta extract, GC/MS chromatographic
analysis was performed on a thermogas chromatograph-mass
spectrometer (model Shimadzu 2010) equipped with DB-5
capillary column (30m long. 0.25mm i.d., film thickness
0.25 𝜇m). The column temperature program was 60∘C for
0min, with 10∘C per min increases to 270∘C; which was
maintained for 30min. The carrier gas was helium at a flow
rate of 1mL/min with split 10 : 1. The detector and injector
temperatureswere bothmaintained at 270∘C.Thequadrupole
mass spectrometer was scanned over the range 28–400 amu
at 1 scan s-1, with an ionising voltage of 70 eV, an ionisation
current of 150Ma, and an ion source temperature of 200∘C.
In order to determine the Kovats index of the components, a
mixture of alkenes (C
9
–C
24
) was added to the crude extract
before injecting in theGC-MS equipment and analysed under
the same conditions as above.The compoundswere identified
by computer searches in the commercial libraries of the
National Institute of Standard and Technology (NIST) and by
their Kovats retention indexes.
2.2. Experimental Animals. Male and female SpragueDawley
(SD) rats were used for the acute and subchronic toxicology
studies. The rats were obtained from the Animal Research
and Service Centre (ARASC), Universiti Sains Malaysia. The
animals were acclimatized to laboratory conditions for 7
days prior to the experiments. The rats were maintained
at a room temperature of 22–24∘C, with a 12 h light/dark
cycle. During acclimatization, the animals were housed in
polycarbonate cages with a standard pellet diet and tap water
ad libitum.The food pellets for the experimental animalswere
purchased from Gold Coin Holdings Sdn. Bhd. (Malaysia).
All procedures in this study were performed according to
the Animal Ethics Committee, Universiti Sains Malaysia,
(USM/Animal Ethics Approval/2011/(74) (375)).
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Figure 1: GC/MS chromatogram of Euphorbia hirta.
2.3. Acute Oral Toxicity Study. An acute toxicity test was
performed according to the Organization of Economic Co-
operation and Development (OECD) guideline 420 for test-
ing of chemicals [14]. Rats of both sexes, aged 6–8 weeks,
old were used. E. hirta methanol extract was dissolved in
10% Tween 20 and administered orally (only once) at a
single dose of 5000mg/kg at a rate of 20mL/kg to both
male and female rats (𝑛 = 12; 6 males and 6 females),
whereas the control group received only 10% Tween 20 as
a vehicle. After administration of E. hirta methanol extract,
rats were observed for 24 h, with special attention given
to the first 4 h and once daily further for a period of 14
days. The rats were weighed and visual observations for
mortality, behavioural pattern (salivation, fur, lethargy, and
sleep), changes in physical appearance, injury, pain, and
signs of illness were conducted once daily during the period.
At the end of the experiment, the rats were anesthetized
through intraperitoneal injection of a cocktail containing
ketamine (60mg/kg) and xylazine (7.5mg/kg). Blood samples
were collected via cardiac puncture into nonheparinized and
EDTA-containing tubes for biochemical and haematological
analyses, respectively. After cardiac puncture, the rats were
euthanized through intraperitonealinjection of a cocktail
containing ketamine (80mg/kg) and xylazine (10mg/kg).The
organs were excised, weighed, and examined macroscopi-
cally.The relative organ weight was calculated. Principal vital
organs (liver, kidney, lung, heart, and spleen) were preserved
in a fixation medium of 10% solution of buffered formalin
for histopathological study. Haematological and biochemical
analyses were performed at Gribbles Pathology (M) Sdn.
Bhd., Penang, Malaysia.
2.4. Subchronic Oral Toxicity Study. The subchronic toxicity
test was performed following the protocol described by the
OECD guideline 408 for testing chemicals [15]. Rats of both
sexes were randomly assigned into five groups: a control
group and four treatment groups (𝑛 = 20; 10 males and
10 females). The E. hirta methanol extract was dissolved in
10% Tween 20 and administered orally on daily basis for
90 days at single doses of 50, 250, and 1000mg/kg, while
the control group received only 10% Tween 20 in distilled
water. An additional group was devised as the satellite
group in order to observe the reverse sign of any toxicity.
The satellite group was orally administered with the extract
at a daily dose of 1000mg/kg/day for 90 days, and there
was no further treatment for the following 28 days before
termination of the study. The extract was freshly prepared
with vehicle on daily basis. The rats were weighed and visual
observations formortality, behavioral pattern (Salivation, fur,
lethargy, and sleep), changes in physical appearance, injury,
pain and signs of illness were conducted once daily during
that period. At the end of the experiment, all animals were
anesthetized through intraperitonealinjection of a cocktail
containing ketamine (60mg/kg) and xylazine (7.5mg/kg).
Blood samples were collected via cardiac puncture into
nonheparinized and EDTA-containing tubes for biochemi-
cal and haematological analyses, respectively. After cardiac
puncture, the rats were euthanized by ketamine/xylazine
(80mg/kg/10mg/kg) overdose. The organs were excised,
weighed, and examined macroscopically. The relative organ
weight was calculated. Principal vital organs (liver, kidney,
lung, heart, and spleen) were preserved in fixationmediumof
10% solution of buffered formalin for histopathological study.
Haematological and biochemical analyses were performed at
Gribbles Pathology (M) Sdn. Bhd., Penang, Malaysia.
2.5. Histopathological Study. After sacrificing the rats, parts
of the liver, kidney, lung, heart, and spleen tissues were
collected for histological studies. The tissues were washed in
normal saline and fixed immediately in 10% formalin for a
period of at least 24 h, dehydrated with alcohol, embedded
in paraffin, cut into 4-5𝜇m thick sections, and stained with
haematoxylin-eosin dye for photomicroscopic observation.
The microscopic features of the organs of male and female
rats were compared with the control group.
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2.6. Statistical Analysis. All values are expressed as mean ±
SEM. Comparisons between groups were performed using
one way analysis of variance (ANOVA) followed by Tukey’s
multiple comparison tests using SPSS statistical software. A
𝑃 value of < 0.05 was considered significant.
3. Results
3.1. Preparation of Euphorbia hirta Methanol Extract. To
standardize the fingerprint, ten batches of E. hirta samples
were analysed with the developed procedure. GC/MS chro-
matogram of E. hirta, as shown in Figure 1. The peaks that
existed in all the ten batches of samples were assigned
as “common peaks” for the E. hirta extract (Figure 1). There
are twenty-two “common peaks” in the fingerprint. Of these
components, the 8 most intense, corresponding to 53.317%
(w/w) of the E. hirta extract, were 2-butanone, 3,3-dimethyl-1
(methylsulfonyl)-, O-[(methylamino)carbonyl]oxime (RT
(retention time): 1.599; Area: 2.225%), 2-furancarboxalde-
hyde, 5-(hydroxymethyl)-(RT: 6.583; area: 2.164%), 1,2,3-ben-
zenetriol (RT: 8.795; area: 5.290%), 1,3,4,5-tetrahydrox-
ycyclohexanecarboxylic acid (RT: 11.863; area: 9.636%),
hexadecanoic acid (RT: 15.088; area: 2.916%), 9,12,15-
Octadecatrienoic acid (RT: 16.754; area: 5.497%), stigmast-
5-en-3-ol (RT: 29.970; 2.836%) and 9,19-cyclolanost-
24-en-3-ol (RT: 32.097; area: 22.753%). The abundant
presence of phytochemicals in whole plant of E. hirta like
flavonoids, alkaloids, saponins, resins, sterols, steroids, acidic
compounds, tannins, glycosides, anthraquinone, phenols
and terpenoids was reported by Kader et al. [16]. Alcoholic
solvents (such as methanol which was used in this study
to prepare E. hirta extract) have been commonly used to
extract polyphenols from natural sources [17]. Moreover,
Pio´ro-Jabrucka et al. [18] also reported the presence of
phenolic compounds in the E. hirta extract.
3.2. Acute Oral Toxicity. Methanolic extract of E. hirta at a
dose of 5000mg/kg had no adverse effect on the behavioural
responses of the tested rats up to 14 days of observation. Phys-
ical observations indicated no signs of changes in the skin,
fur, eyes mucous membrane, behaviour patterns, tremors,
salivation, and diarrhoea of the rats. There was no mortality
observed at the tested dose nor was the weight loss in the
rats affected (Figure 2). There were generally no significant
differences observed in the relative organ weights in this
study (Table 1). However, significant differences (𝑃 < 0.05)
were seen in the liver and spleen in the treated groups when
compared with the control group. From the present study it
was seen that there was no significant change in the haema-
tological and biochemical parameters in the E. hirta extract
treated group compared to the normal control group (Tables
2 and 3). Gross examination at autopsy and histopathological
evaluations of the various organs stained with haematoxylin
and eosin revealed no significant differences (Figure 5). The
LD
50
of this plant was therefore estimated to be more than
5000mg/kg.
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Figure 2: Mean body weight of rats receiving Euphorbia hirta
extract for 14 days. Values are expressed as mean ± SEM (𝑛 = 6
for each group). ∗P values < 0.05 were considered significant using
one way ANOVA followed by Tukey’s multiple comparison tests.
Asterisks denote significant difference compared to control.
Table 1: Relative organ weights of rats receiving single dose of
Euphorbia hirta extract for 14 days.
Organs
Treatment
Control Euphorbia hirta extracts5000mg/kg
Male
Heart 0.45 ± 0.02 0.42 ± 0.02
Liver 3.52 ± 0.13 3.15 ± 0.10∗
Spleen 0.30 ± 0.02 0.36 ± 0.01∗
Kidneys 0.83 ± 0.02 0.85 ± 0.02
Lungs 0.67 ± 0.03 0.63 ± 0.06
Female
Heart 0.46 ± 0.02 0.44 ± 0.02
Liver 3.69 ± 0.16 3.56 ± 0.15
Spleen 0.42 ± 0.04 0.38 ± 0.02
Kidneys 0.90 ± 0.07 0.81 ± 0.04
Lungs 0.82 ± 0.03 0.83 ± 0.05
Values are expressed as mean ± SEM (𝑛 = 6 for each group).
Relative organ weight was calculated as (organ weight/body weight) × 100%
∗
𝑃 values < 0.05 were considered significant using one-way ANOVA
followed by Tukey’s multiple comparison tests. Asterisks denote significant
difference compared to control.
3.3. Subchronic Oral Toxicity
3.3.1. Clinical Signs, Necropsy Findings, and Food and Water
Consumption. Daily oral administration of E. hirta extract
for 90 days did not induce any obvious symptom of toxicity
in rats of both sexes, including the highest dose tested
at 1000mg/kg body weight. No deaths or obvious clinical
BioMed Research International 5
Table 2: Effect of Euphorbia hirta extract on haematological parameters in acute oral toxicity study.
Unit
Treatment
Control Euphorbia hirta extracts5000mg/kg
Male
Haemoglobin g/L 154.33 ± 1.96 150.17 ± 2.57
Total red blood cells 1012/L 7.83 ± 0.15 8.14 ± 0.27
Packed cells volume L/L 0.46 ± 0.00 0.46 ± 0.00
Mean corpuscular volume fL 59.00 ± 0.77 56.17 ± 1.19
Mean corpuscular Hb pg 19.67 ± 0.21 18.67 ± 0.56
Mean corpuscular Hb conc g/L 334.50 ± 5.89 330.17 ± 8.67
Red blood cells distribution width % 14.37 ± 0.79 14.57 ± 1.044
Total white blood cells 109/L 7.27 ± 0.97 9.02 ± 1.70
Neutrophils % 20.83 ± 3.03 27.33 ± 3.27
Lymphocytes % 73.33 ± 2.28 69.33 ± 3.17
Monocytes % 3.00 ± 0.73 2.00 ± 0.37
Platelet count 109/L 866.00 ± 120.33 1140.33 ± 50.64
Female
Haemoglobin g/L 141.17 ± 5.52 142.83 ± 4.90
Total red blood cells 1012/L 7.48 ± 0.26 7.28 ± 0.18
Packed cells volume L/L 0.41 ± 0.03 0.44 ± 0.011
Mean corpuscular volume fL 55.33 ± 0.01 60.50 ± 1.18∗
Mean corpuscular Hb pg 19.00 ± 0.26 19.67 ± 0.42
Mean corpuscular Hb conc g/L 341.83 ± 6.67 324.17 ± 6.89
Red blood cells distribution width % 12.30 ± 0.22 13.33 ± 1.11
Total white blood cells 109/L 8.93 ± 0.43 9.03 ± 0.97
Neutrophils % 19.17 ± 3.05 16.00 ± 1.84
Lymphocytes % 74.33 ± 3.34 79.83 ± 1.30
Monocytes % 4.50 ± 0.99 3.67 ± 1.085
Platelet count 109/L 844.67 ± 147.75 995.67 ± 55.01
Values are expressed as mean ± SEM (𝑛 = 6 for each group).
∗
𝑃 values < 0.05 were considered significant using one way ANOVA followed by Tukey’s multiple comparison tests. Asterisks denote significant difference
compared to control.
signs were found in any groups throughout the experimental
period. Physical observation of the treated rats throughout
the study indicated that none of them showed signs of toxicity
in their skin, fur, eyes, mucus membrane, or behavioural
changes, diarrhoea, tremors, salivation, sleep, and coma.
Normal body weight gains were observed during the study
period compared to the control group (Figures 3 and 4). No
abnormal gross findings were observed in the necropsies of
any of the rats. The food and water consumptions of the
treated rats, whichweremeasured throughout the study, were
also not significantly different compared to the control rats.
3.3.2. Relative OrganWeights (ROW) ofMale and Female Rats.
Relative organ weights of 90-day treated rats are shown in
Table 4. The relative organ weight of each organ recorded at
necropsy in the treatment groups did not show a significant
difference (𝑃 > 0.05) compared to the control (Table 4).
3.3.3. Haematology and Clinical Biochemistry Analysis. The
effects of subchronic administration of E. hirta extract on
haematological and biochemicalparameters are presented in
Tables 5 and 6. Most haematology measures (haemoglobin,
total red blood cells, red blood cells distribution width, total
white blood cells, neutrophils, lymphocytes, monocytes and
platelet count) in treated rats were not significantly different
from the controls, with the exception of marginal variations
in certain parameters (Table 5). Moreover, the E. hirta extract
had no effect on the serum electrolytes, such as sodium,
potassium, and chloride. The kidney function parameters
(urea, creatinine, and uric acid) did not reveal any relevant
changes following administration of E. hirta extract. No sta-
tistically significant differences in liver function parameters
(ALT, AST, and alkaline phosphatase) were noted with the
exception of marginal variations. No significant changes in
total protein, globulin and albumin were noted (Table 6).
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Table 3: Effect of Euphorbia hirta extract on biochemical parameters in acute oral toxicity study.
Unit
Treatment
Control Euphorbia hirta extracts5000mg/kg
Male
Sodium mmol/L 140.83 ± 0.70 140.83 ± 0.60
Potassium mmol/L 4.37 ± 0.29 4.75 ± 0.35
Chloride mmol/L 102.83 ± 0.83 104.50 ± 1.06
Urea mmol/L 5.65 ± 0.52 6.083 ± 0.36
Creatinine 𝜇mol/L 24.17 ± 2.30 25.67 ± 3.21
Uric acid mmol/L 0.15 ± 0.03 0.17 ± 0.03
Total protein g/L 61.50 ± 1.82 62.67 ± 0.95
Albumin g/L 29.67 ± 0.84 31.67 ± 0.67
Globulin g/L 31.83 ± 1.17 31.00 ± 1.18
Albumin/globulin ratio 0.93 ± 0.03 1.02 ± 0.05
Alkaline phosphatase U/L 201.83 ± 41.45 231.00 ± 11.90
AST U/L 196.00 ± 7.31 184.33 ± 19.22
ALT U/L 44.67 ± 1.45 49.167 ± 3.65
Female
Sodium mmol/L 140.00 ± 0.82 139.83 ± 0.91
Potassium mmol/L 4.27 ± 0.19 4.33 ± 0.28
Chloride mmol/L 105.17 ± 1.35 102.67 ± 1.23
Urea mmol/L 8.12 ± 0.59 7.38 ± 0.61
Creatinine 𝜇mol/L 36.33 ± 6.03 33.33 ± 1.31
Uric acid mmol/L 0.11 ± 0.00 0.15 ± 0.03
Total protein g/L 62.33 ± 1.43 64.50 ± 1.80
Albumin g/L 31.50 ± 0.67 32.33 ± 1.65
Globulin g/L 30.83 ± 1.51 32.17 ± 1.30
Albumin/globulin ratio 1.02 ± 0.05 1.00 ± 0.07
Alkaline phosphatase U/L 142.17 ± 24.23 194.83 ± 15.74
AST U/L 139.83 ± 17.18 202.17 ± 22.27
ALT U/L 32.67 ± 2.96 46.33 ± 1.86
Values are expressed as mean ± SEM (𝑛 = 6 for each group).
∗
𝑃 values < 0.05 were considered as significant using one way ANOVA followed by Tukey’s multiple comparison tests. Asterisks denote significant difference
compared to control.
3.3.4. Macropathology and Histopathology. Macroscopic ex-
amination of the vital organs of treated animals revealed
no abnormalities in the colour or texture when compared
with the organs of the control group. The light microscopy
examinations of the transverse section of E. hirta extract
and organs of the control group rats are shown in Figure 6.
Histopathological examination of the control group and
E. hirta extract treated rats showed normal structure and
absence of any gross pathological lesion in organs.
4. Discussion
For centuries, natural products, such asmedicinal plants have
been the basis for the treatment of various ailments [19]. In
screening natural products for the pharmacological activity,
assessment and evaluation of the toxic characteristics of a
natural product extract, fraction, or compound are usually
an initial step. Regardless of the pharmacological beneficial
effects of E. hirta, detailed knowledge about the chronic
toxicology of this famous herb is lacking. Hence, the current
study was undertaken to evaluate and focus on the acute and
chronic toxicity of E. hirta in an animal model.
During the evaluation of the toxic characteristics of
medicinal plants, the determination of LD
50
is usually an
initial step to be conducted.Data from the acute toxicity study
may (a) serve as the basis for classification and labelling; (b)
provide initial information on the mode of toxic action of
a substance; (c) help arrive at a dose of a new compound;
(d) help in dose determination in animal studies; and (e)
help determine LD
50
values that provide many indices of
potential types of drug activity [5]. Moreover, if a high dose
(e.g., 5,000mg/kg) is found to be survivable, no further
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Table 4: Relative organ weights of rats treated with Euphorbia hirta extract in subchronic toxicity study.
Organs Control Euphorbia hirta
50mg/kg 250mg/kg 1000mg/kga 1000mg/kgb
Male
Heart 0.44 ± 0.01 0.43 ± 0.02 0.39 ± 0.01 0.41 ± 0.01 0.42 ± 0.01
Liver 2.96 ± 0.08 3.04 ± 0.15 3.02 ± 0.05 2.98 ± 0.07 3.07 ± 0.09
Spleen 0.29 ± 0.01 0.28 ± 0.02 0.27 ± 0.01 0.26 ± 0.02 0.27 ± 0.01
Kidneys 0.72 ± 0.01 0.75 ± 0.01 0.71 ± 0.02 0.73 ± 0.02 0.67 ± 0.03
Lungs 0.90 ± 0.08 0.81 ± 0.07 0.83 ± 0.1 0.72 ± 0.03 0.73 ± 0.04
Female
Heart 0.46 ± 0.02 0.45 ± 0.02 0.45 ± 0.02 0.45 ± 0.01 0.42 ± 0.01
Liver 3.11 ± 0.14 3.35 ± 0.07 3.26 ± 0.02 3.32 ± 0.10 3.27 ± 0.07
Spleen 0.36 ± 0.02 0.32 ± 0.01 0.30 ± 0.02 0.30 ± 0.02 0.30 ± 0.01
Kidneys 0.75 ± 0.02 0.78 ± 0.02 0.75 ± 0.01 0.75 ± 0.04 0.70 ± 0.04
Lungs 0.79 ± 0.04 0.93 ± 0.11 0.88 ± 0.03 0.87 ± 0.05 0.70 ± 0.01
Values are expressed as mean ± SEM (𝑛 = 10 for each group).
Relative organ weight was calculated as (organ weight/body weight) × 100%.
aA group was treated with methanol extract of Euphorbia hirta at 1000mg/kg/day for 90 days.
bA satellite group was treated with the methanol extract of Euphorbia hirta at 1000mg/kg/day for 90 days followed by no treatment for 28 days.
∗
𝑃 values < 0.05 were considered significant using one way ANOVA followed by Tukey’s multiple comparison tests. Asterisks denote significant difference
compared to control.
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Figure 3: Mean body weight of male rats receiving Euphorbia hirta
extract for 90 days. Values are expressed as mean ± SEM (𝑛 = 6
for each group). ∗P values < 0.05 were considered significant using
one way ANOVA followed by Tukey’s multiple comparison tests.
Asterisks denote significant difference compared to control.
acute testing will be conducted [20]. In this study, E. hirta
extract at a dose of 5000mg/kg had no adverse effect on
the tested rats up to 14 days of observation. The significant
changes in the relative weights of the liver and spleen
in the presence of E. hirta extract may indicate that the
extract might have toxic potential on the liver and spleen.
However, it could be argued that these changes may not be
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Figure 4:Mean bodyweight of female rats receivingEuphorbia hirta
extract for 90 days. Values are expressed as mean ± SEM (𝑛 = 6
for each group). ∗P values < 0.05 were considered significant using
one way ANOVA followed by Tukey’s multiple comparison tests.
Asterisks denote significant difference compared to control.
toxicologically significant, as they were not corroborated by
the biochemical and histomorphology findings. Therefore,
this study indicates that E. hirta extract does not cause acute
toxicity effects at the dose tested and with an LD
50
value
greater than 5000mg/kg. In principle, the limit test method
is not intended for determining a precise LD
50
value, but
it serves as a suggestion for classifying the crude extract
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Table 5: Effect of Euphorbia hirta extract on hematological parameters in subchronic toxicity study.
Unit Control Euphorbia hirta
50mg/kg 250mg/kg 1000mg/kga 1000mg/kgb
Male
Haemoglobin g/L 144.30 ± 2.91 143.00 ± 3.36 151.40 ± 4.12 148.80 ± 3.35 138.30 ± 4.92
Total red blood cells 1012/L 7.84 ± 0.18 7.75 ± 0.18 8.22 ± 0.26 8.14 ± 0.18 7.55 ± 0.27
Packed cell volume L/L 0.45 ± 0.01 0.44 ± 0.01 0.46 ± 0.01 0.47 ± 0.01 0.44 ± 0.01
Mean corpuscular volume fL 57.70 ± 0.45 57.00 ± 0.65 56.50 ± 0.70 57.30 ± 0.73 58.60 ± 0.99
Mean corpuscular Hb pg 18.50 ± 0.17 18.50 ± 0.22 18.40 ± 0.16 18.30 ± 0.26 18.30 ± 0.34
Mean corpuscular Hb conc g/L 319.60 ± 2.29 323.80 ± 1.81 327.00 ± 2.05 319.50 ± 3.28 313.30 ± 3.08
Red blood cells Distribution width % 15.55 ± 0.39 15.32 ± 0.32 15.47 ± 0.45 16.96 ± 0.34 16.24 ± 0.40
Total white blood cells 109/L 5.00 ± 0.76 4.99 ± 0.87 5.97 ± 0.91 4.77 ± 0.26 5.72 ± 0.75
Neutrophils % 26.90 ± 2.05 32.70 ± 1.67 28.60 ± 1.11 31.7 ± 1.91 28.00 ± 2.67
Lymphocytes % 69.20 ± 2.22 62.00 ± 1.78 67.30 ± 1.41 64.8 ± 2.25 66.50 ± 2.63
Monocytes % 2.70 ± 0.40 4.10 ± 0.77 3.60 ± 0.65 2.10 ± 0.41 3.80 ± 0.36
Platelet count 109/L 926.60 ± 42.34 980.80 ± 51.44 1005.20 ± 37.24 968.70 ± 27.91 947.20 ± 48.18
Female
Haemoglobin g/L 143.70 ± 4.05 140.50 ± 2.95 142.30 ± 3.45 144.80 ± 4.87 142.70 ± 4.24
Total red blood cells 1012/L 7.60 ± 0.23 7.48 ± 0.16 7.45 ± 0.17 7.65 ± 0.26 7.31 ± 0.23
Packed cell volume L/L 0.44 ± 0.01 0.44 ± 0.01 0.44 ± 0.01 0.46 ± 0.01 0.45 ± 0.01
Mean corpuscular volume fL 58.30 ± 0.63 58.20 ± 0.79 59.10 ± 0.60 60.20 ± 0.70 62.20 ± 1.07
Mean corpuscular Hb pg 18.80 ± 0.20 18.70 ± 0.15 19.20 ± 0.20 18.90 ± 0.10 19.60 ± 0.16
Mean corpuscular Hb conc g/L 324.40 ± 1.67 323.30 ± 3.96 323.30 ± 1.71 314.90 ± 3.02 314.90 ± 4.23
Red blood cell distribution width % 14.01 ± 0.30 13.48 ± 0.19 13.19 ± 0.22 14.8 ± 0.25 15.07 ± 0.38
Total white blood cells 109/L 6.53 ± 1.54 7.30 ± 1.19 5.19 ± 0.73 6.33 ± 1.01 8.09 ± 1.03
Neutrophils % 24.50 ± 1.86 22.20 ± 3.34 23.00 ± 1.80 28.50 ± 4.43 20.30 ± 1.94
Lymphocytes % 69.90 ± 1.64 71.60 ± 3.28 71.00 ± 2.13 65.50 ± 4.80 74.30 ± 2.26
Monocytes % 4.40 ± 0.43 5.80 ± 0.80 5.00 ± 0.60 3.70 ± 0.58 3.90 ± 0.55
Platelet count 109/L 890.40 ± 68.48 914.20 ± 24.01 931.30 ± 50.95 831.50 ± 86.06 927.10 ± 33.27
Values are expressed as mean ± SEM (𝑛 = 10 for each group).
aA group was treated with methanol extract of Euphorbia hirta at 1000mg/kg/day for 90 days.
bA satellite group was treated with the methanol extract of Euphorbia hirta at 1000mg/kg/day for 90 days followed by no treatment for 28 days.
∗
𝑃 values < 0.05 were considered significant using one way ANOVA followed by Tukey’s multiple comparison tests. Asterisks denote significant difference
compared to control.
based on the expectation at which dose level the animals are
expected to survive [21]. According to the chemical labelling
and classification of acute systemic toxicity recommended by
OECD, the crude extract of E. hirta extract was assigned class
5 status (LD
50
> 5000mg/kg), which was the lowest toxicity
class. According to the study byKennedy et al. [22] substances
with LD
50
values higher than 5000mg/kg by oral route are
regarded as being safe or practically nontoxic.However,many
medicinal plants have also been reported to be toxic to both
humans and animals.Therefore, it should be emphasized that
the traditional use of any plant for medicinal purposes, by no
means, guarantees the safety of such plant. Furthermore, the
data of the acute and subchronic toxicity studies onmedicinal
plants or preparations derived from them should be obtained
in order to increase the confidence in its safety to humans,
particularly for use in the development of pharmaceuticals
[5]. Choosing the appropriate tests and dosing regimens that
will demonstrate an adequate margin of exposure is a critical
step in establishing human safety. Since no toxic effects were
found during the acute toxicity study, further evaluation was
conducted to evaluate the subchronic toxicity of E. hirta
extract up to 90 days in rats to prepare the comprehensive
toxicology data of this ancient medicinal plant.
Subchronic studies assess the undesirable effects of con-
tinuous or repeated exposure of plant extracts or compounds
over a portion of the average life span of experimental ani-
mals, such as rodents. Specifically, they provide information
on target organ toxicity and are designed to identify noob-
servable adverse effect level [20]. Subchronic evaluation can
also help to determine appropriate dose regimens for longer-
term studies. Consequently, in this study the subchronic
toxicity E. hirta extract was evaluated in rats at doses of 50–
1000mg/kg/day for 90 days. Consideration should be given to
an additional satellite group treated with top dose group for
observation of reversibility, persistence or delayed occurrence
of systemic toxic effects and recovery from toxic effects, for
at least 14 days after treatment. Satellite groups are groups of
animals included in the design and conduct of a toxicity study.
This group will be treated and housed under the conditions
identical to those of the animals from main experimental
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Table 6: Effect of Euphorbia hirta extract on biochemical parameters in subchronic toxicity study.
Unit Control Euphorbia hirta
50mg/kg 250mg/kg 1000mg/kga 1000mg/kgb
Male
Sodium mmol/L 143.20 ± 0.49 142.80 ± 0.85 141.90 ± 0.59 142.20 ± 0.51 142.60 ± 0.43
Potassium mmol/L 4.13 ± 0.09 4.42 ± 0.14 4.03 ± 0.123 4.29 ± 0.19 4.63 ± 0.16
Chloride mmol/L 103.20 ± 0.44 102.70 ± 0.62 102.90 ± 0.66 102.00 ± 0.71 103.10 ± 0.95
Urea mmol/L 6.98 ± 0.26 7.41 ± 0.42 7.12 ± 0.31 7.06 ± 0.29 7.12 ± 0.35
Creatinine 𝜇mol/L 30.30 ± 0.72 25.50 ± 1.93 26.30 ± 1.61 29.70 ± 1.08 30.70 ± 1.19
Uric acid mmol/L 0.10 ± 0.00 0.11 ± 0.01 0.14 ± 0.04 0.12 ± 0.02 0.11 ± 0.01
Total protein g/L 65.70 ± 1.10 67.00 ± 1.33 65.60 ± 1.21 67.00 ± 1.46 65.40 ± 1.16
Albumin g/L 30.50 ± 0.67 28.40 ± 0.88 29.30 ± 0.94 30.60 ± 0.72 30.70 ± 0.56
Globulin g/L 35.20 ± 0.90 38.60 ± 1.76 36.30 ± 0.86 36.40 ± 0.90 34.70 ± 1.14
Albumin/globulin ratio 0.88 ± 0.03 0.76 ± 0.05 0.80 ± 0.03 0.85 ± 0.02 0.90 ± 0.04
Alkaline phosphatase U/L 208.10 ± 7.17 256.70 ± 13.41 269.30 ± 17.12 230.60 ± 14.23 237.50 ± 21.25
AST U/L 232.10 ± 7.95 270.40 ± 23.32 211.90 ± 8.40 222.30 ± 7.63 199.40 ± 15.35
ALT U/L 56.20 ± 2.30 55.10 ± 1.49 57.70 ± 2.76 65.80 ± 4.77 63.40 ± 4.92
Female
Sodium mmol/L 141.20 ± 0.66 139.90 ± 0.74 138.90 ± 0.53 140.00 ± 0.61 139.90 ± 0.43
Potassium mmol/L 4.07 ± 0.12 4.28 ± 0.00 4.13 ± 0.18 4.09 ± 0.09 4.37 ± 0.18
Chloride mmol/L 103.30 ± 0.67 102.80 ± 1.03 102.30 ± 0.56 103.30 ± 1.11 103.30 ± 0.73
Urea mmol/L 6.93 ± 0.29 5.83 ± 0.15 6.25 ± 0.35 6.88 ± 0.38 7.38 ± 0.36
Creatinine 𝜇mol/L 29.70 ± 1.61 27.00 ± 0.80 28.10 ± 1.16 36.10 ± 1.59 36.60 ± 2.35
Uric acid mmol/L 0.12 ± 0.00 0.12 ± 0.01 0.14 ± 0.02 0.13 ± 0.01 0.13 ± 0.01
Total protein g/L 68.00 ± 1.42 69.20 ± 1.61 71.50 ± 2.17 69.40 ± 1.65 67.40 ± 0.90
Albumin g/L 30.20 ± 1.08 30.40 ± 0.60 30.80 ± 0.85 31.70 ± 1.25 33.40 ± 0.64
Globulin g/L 37.80 ± 1.31 38.80 ± 1.77 40.70 ± 1.97 37.70 ± 1.82 34.00 ± 1.02
Albumin/globulin ratio 0.81 ± 0.05 0.79 ± 0.04 0.76 ± 0.04 0.86 ± 0.06 0.97 ± 0.05
Alkaline phosphatase U/L 178.00 ± 11.08 221.60 ± 16.48 214.00 ± 23.56 142.50 ± 9.28 153.80 ± 25.83
AST U/L 236.6 ± 12.50 216.5 ± 13.91 225.5 ± 10.62 210.7 ± 8.56 187 ± 7.60
ALT U/L 53.1 ± 2.9 44.7 ± 2.21 42.4 ± 3.4 47.4 ± 3.27 47.7 ± 1.80
Values are expressed as mean ± SEM (𝑛 = 10 for each group).
aA group was treated with methanol extract of Euphorbia hirta at 1000mg/kg/day for 90 days.
bA satellite group was treated with the methanol extract of Euphorbia hirta at 1000mg/kg/day for 90 days followed by no treatment for 28 days.
∗
𝑃 values < 0.05 were considered significant using one way ANOVA followed by Tukey’s multiple comparison tests. Asterisks denote significant difference
compared to control.
group but used mainly for toxicokinetics [15]. The satellite
group in this study was orally administered with the E. hirta
extract at a daily dose of 1000mg/kg/day for 90 days, and
no further treatment for the following 28 days before the
termination of the study. However, in the satellite group no
reversibility or persistence of any toxic effects was observed
in this studywhich further verified nontoxic nature of E. hirta
extract tested in this study.
Administration of extracts of E. hirta for 90 days pro-
duced no clinical signs for toxicity or mortality in either sex.
In addition, the treated rats did not show any significant
alteration in water or food consumption (data not shown).
Significant reduction in food and water intake is suggested
as being responsible for the observed decrement in body
weight gain. Loss of appetite is often synonymous with
weight loss due to disturbances in carbohydrate, protein or
fat metabolisms [23]. Moreover, at higher doses, crude plant
extracts may metabolise to a toxic end product, which could
interfere with gastric function and decreased food conversion
efficiency [24]. Interestingly, the food and water intakes were
found to be unaltered during the 90-day treatment period
when compared to a control group in this study. Furthermore,
the diets andwater werewell-accepted by the rats treatedwith
E. hirta extract suggesting the extract did not possibly cause
any alterations in carbohydrate, protein or fat metabolism
in these experimental animals. It also shows that the E.
hirta extract did not adversely interfere with the nutritional
benefits, such as weight gain and stability of the appetite,
which are expected for animals that are continually supplied
with food andwater ad libitum. Also, the extract is safe by oral
route in relation to its folkloric practice in the administration
of medicinal herbs through oral route to treat the patients.
Therefore, E. hirta extract can be considered as non-toxic up
to the said dose.
The body weight changes serve as a sensitive indication
of the general health status of animals [25]. However, weight
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Figure 5: Effects of the 5000mg/kg of Euphorbia hirta extract on various rat organ histomorphologies in acute oral toxicity study. (a), (b),
(k), and (l): heart; (c), (d), (m), and (n): kidney; (e), (f), (o), and (p): liver; (g), (h), (q), and (r): lung; (i), (j), (s), and (t): spleen.
gains were observed in all animals administered with E.
hirta extract. It can be stated that the E. hirta extract did
not interfere with the normal metabolism of animals as
corroborated by the nonsignificant difference from animals
in the vehicle control group. The significant increment in
food and water intake is considered as being responsible for
the increment in body weight gain. As mentioned earlier the
loss of appetite is often synonymous with weight loss due
to disturbances in the metabolism of carbohydrate, protein,
or fat [26]. Therefore, the normal food and water intake
(𝑃 > 0.05) without loss of appetite are suggested as being
responsible for the observed increment in body weight in
this study. In addition, the observed increase in body weight
could be attributed to the nutritive components in the E.
hirta extract [26, 27]. Interestingly, it was noted that the dose
1000.00mg/kg/day further increases the body weight in both
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Figure 6: Effects of the 1000mg/kg of Euphorbia hirta extract on various rat organ histomorphologies in subchronic toxicity study. (a), (b),
(k), and (l): heart; (c), (d), (m), and (n): kidney; (e), (f), (o), and (p): liver; (g), (h), (q), and (r): lung; (i), (j), (s), and (t): spleen.
male and female rats after the 12th week of treatment with
E. hirta extract. Fatness is characterized by increased adipose
tissue mass that results from both increased fat cell number
and increased fat cell size. Adipose tissue is a dynamic organ
that plays an important role in energy balance and changes
in mass according to the metabolic requirements of the
organism [28]. Moreover, it was reported that excess energy
intake and reduced energy expenditure result in abnormal
excessive growth of white adipose tissue (WAT), which can
lead to the development of obesity [17, 29]. The current
research findings have suggested that E. hirta extract with the
dose 1000.00mg/kg/day may not prevent the accumulation
of WAT in rats after the 12th week of treatment. However,
further mechanism studies are needed to clarify the obesity
effects of E. hirta extract after the 12th week of treatment.
Similarly, no significant changes in the weights of the
heart, liver, spleen, kidneys, or lungs were observed, suggest-
ing that administration of E. hirta extract at the subchronic
12 BioMed Research International
oral doses had no effect on the normal growth. The use-
fulness of weighing organs in toxicity studies includes their
sensitivity to predict toxicity, enzyme induction, physiologic
perturbations, and acute injury; it is frequently a target organ
of toxicity; it correlates well with histopathological changes;
there is little interanimal variability; historical control range
data are available [30]. The relative organs weights have
been observed in toxicity studies to be a relatively sensitive
indicator for particular organs, and, thereafter, define toxicity
as significant changes observed in those particular organs
[31]. The results of this study revealed that the essential
organs, such as heart, liver, spleen, kidneys, and lungs, neither
were adversely affected nor showed clinical signs for toxicity
throughout the treatment. Since there was no reduction in
body and relative organ weights of the treated animals at any
of the doses tested, we concluded that the extract is nontoxic
to the analysed organs.
The serum haematology and clinical biochemistry analy-
ses were done to evaluate the possible alterations in hepatic
and renal functions influenced by the extracts. Liver and
kidney function analysis is very important in the toxicity
evaluation of drugs and plant extracts as they are both
necessary for the survival of an organism [32]. High levels
of ALT, AST, and alkaline phosphatase are reported in liver
diseases or hepatotoxicity [33].The nonsignificant changes in
ALT, AST, and alkaline phosphatase in both male and female
rats at all doses suggest that subchronic administration of
E. hirta extract does not affect the hepatocyte function in
the rats. A decrease in total protein, albumin, and globulin
is a sign of the reduced synthetic function of the liver or
might be due to impaired hepatocellular function. Low serum
albumin content may suggest infection or continuous loss
of albumin [34, 35]. Thus, the insignificant change in serum
concentration of total protein, albumin and globulin in the E.
hirta extract treated and control group further confirms that
the extract does not damage the hepatocellular or secretory
functions of the liver at any of the doses tested. Renal
dysfunction can be assessed by concurrent measurements of
urea, creatinine and uric acid and their normal levels reflect
at reduced likelihood of renal problems [36]. In the present
study, changes in plasma urea, creatinine, and uric acid levels
in E. hirta extract treated groups showed non-significant
differences indicating a normal renal function.
Evaluation of haematological parameters can be used to
determine the extent of the deleterious effect of E. hirta
extract on the blood of an animal. It can also be used to
explain blood relating functions of a plant extract or its
products [37]. Furthermore, such analysis is relevant to risk
evaluation as changes in the haematological system have
higher predictive value for human toxicity when the data
are translated from animal studies [38]. A haemogram was
undertaken for all the E. hirta extract treated and control
groups and the results show no significant effects. The non-
significant effect of the extract on total red blood cells, mean
corpuscular volume, mean corpuscular Hb, and platelets
indicates that the E. hirta extract does not affect the erythro-
poiesis, morphology, or osmotic fragility of the red blood
cells [39]. Leukocytes are the first line of cellular defence that
respond to infectious agents, tissue injury, or inflammatory
process. Furthermore, no significant changes were observed
in the neutrophils, lymphocytes, and monocytes in the E.
hirta, which further confirmed the above findings. A normal
haematological profile of E. hirta extract treated groups also
further justified the non-toxic nature of E. hirta extract.
The macroscopic examinations of the organs of rats
treated with various doses of E. hirta extract did not show
any changes in colour compared with control group rats’
organs. Hypertrophy of organs is first hand indication of
toxicity of chemical or biological substance. However, no
hypertrophy of organs was observed in this study amongst all
the groups studied. In addition, themicroscopic examination
revealed that none of the organs from the extract treated rats
showed any alteration in cell structure or any unfavourable
effects when viewed under the light microscope using
multiple magnification powers. No pathologies were
recorded in the histological sections of the vital organs
(heart, liver, spleen, kidney, and lung) of the control group.
Generally, any damage to the parenchymal liver cells results
in elevations of both transaminases in the blood [40]. Thus,
the non-significant increases observed in ALT, AST, and
alkaline phosphatase activities strongly suggest that the
subchronic administration of E. hirta extract did not alter
the hepatocytes and, consequently, the metabolism of the
rats as observed in the histopathology observations of liver
tissue. Equally, there was also no significant increase in urea,
creatinine, and uric acid in the subchronic administration
of E. hirta extract when compared to the control group. Any
rise in urea, creatinine and uric acid levels is only observed
if there is marked damage to functional nephrons [41].
This finding was further confirmed by histopathological
observations of the kidney tissue in this study. Therefore, the
results recorded in this study demonstrate that the E. hirta
extract did not alter the liver or renal function and further
support the non-toxic nature of E. hirta extract.
5. Conclusion
In light of these findings, we may conclude that E. hirta
extract is not toxic in all the doses studied herein and did not
produce any toxic signs or evident symptoms at acute and
subchronic oral toxicity. E. hirta extract did not cause any
lethality or produce any remarkable histopathological signs
or serum chemical alteration.The preliminary results suggest
promising alternatives for exploring therapeutic and pharma-
ceutical interest inE. hirta extract with a reduction of possible
adverse effects. Further studies to determine the effects of E.
hirta extract on an animal foetus, on pregnant animals, and
their reproductive capacity are needed to complete the safety
profile of this herb.
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